UOC
ZNTL icon

UBS O'Connor’s Zentalis Pharmaceuticals ZNTL Stock Holding History

UBS O'Connor’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,527
Closed -$293K – 348
2022
Q3 		$293K Sell
13,527
-65,600
-83% -$1.79M ﹤0.01% 832
2022
Q2 		$2.22M Buy
+79,127
New +$2.1M 0.02% 626

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

UBS O'Connor's ZNTL Position: Q4 2022 in Review

UBS O'Connor sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2022, closing a stake of 13,527 shares — an estimated $293K sold.

UBS O'Connor first reported a position in ZNTL in Q2 2022 and held it in 2 quarters. The position peaked at $2.22M in Q2 2022. 106 funds tracked by Wall St. Rank hold ZNTL as of Q4 2022.

  • UBS O'Connor reported no remaining Zentalis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • UBS O'Connor sold 13,527 Zentalis Pharmaceuticals shares in Q4 2022, an estimated $293K.
  • UBS O'Connor first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • UBS O'Connor's Zentalis Pharmaceuticals position peaked at $2.22M in Q2 2022.
  • 106 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.